(TSXV: GRD) (OTCQB: GRDAF)- Grounded Lithium Corp. (“GLC” or the “Company”) announces completion of the 2024 field program and provides an update on the ongoing Pre-Feasibility Study (“PFS”) for the Kindersley Lithium Project (“KLP”). The Company, together with its strategic partner Denison Mines Corp. (“Denison”), completed a field drill program at the KLP's original 4-15-33-23W3 […]

— Bell Let's Talk invites everyone to join Canada's 15th national day for mental health and take action to address the growing youth mental health crisis — Canadians can donate $5 by texting “YOUTH” to 45678 with Bell matching up to a total of $1 million; 100% of the proceeds going to six youth mental

$75 million ofvaping tax revenues (2023/24) came from high-school students, an amount that is more than twice as much as Health Canada spends on all activities to reduce smoking or vaping. National Non-Smoking Week is an annual occasion to acknowledge the harms of tobacco industry products and to commit to individual and societal action to

(NASDAQ:OKYO), LONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that

KINGSTOWN, St. Vincent and the Grenadines, Jan. 22, 2025 (GLOBE NEWSWIRE) — WOO X, a leading global centralized crypto trading platform known for its innovative trading solutions, has launched an exclusive reward event, with 0.1 bps of all spot and perpetual trading volumes allocated directly to WOO stakers from January 23 to February 6. “This

(NasdaqGM:CHRS), – Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor activity was observed across both viral and non-viral etiologies – – Data support continued evaluation of casdozokitug with VEGF and PD-(L)1 blockade in HCC – – Randomized

(NasdaqGM:AXSM), NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year of 2024 on Tuesday, February 18, 2025, before the opening

(NYSE MKT:CATX), SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that an abstract on updated interim results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET (NCT05636618) has been accepted as

(NasdaqGM:NRIX), SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of John Northcott as chief commercial officer (CCO). Mr. Northcott has over 20 years of commercial experience, including

(NASDAQ:HSDT), –PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis– –Statistically significant findings in DGI (Dynamic Gait Index) during Phase 1 and Phase 2 among the 38 subjects who completed the treatment protocol showing a total mean improvement of 5.00 (4.1